Court rejects patent infringement claims in covid-19 sham litigation case

A covid-19 test manufacturer accusing a rival of sham litigation to monopolise the market for genetic testing using saliva has proven it did not infringe upon any patents, but its new antitrust claims are barred by the First Amendment, a California federal court has ruled.

Unlock unlimited access to all Global Competition Review content